Free Trial

SAB Biotherapeutics (SABSW) 10K Form and Latest SEC Filings 2026

SAB Biotherapeutics logo
$0.0074 0.00 (-26.87%)
As of 03:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest SAB Biotherapeutics SEC Filings & Recent Activity

SAB Biotherapeutics (NASDAQ:SABSW) has submitted 226+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in SAB Biotherapeutics's financial statements. The most recent filing was a Form 8-K submitted on October 13, 2026.

8-K
SAB Biotherapeutics Files Current Report on Oct. 13, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
SAB Biotherapeutics Files Quarterly Report on Aug. 6, 2026

The 10-Q contains SAB Biotherapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

SAB Biotherapeutics SEC Filing History

Browse SAB Biotherapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
10/13/2026 7:36 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2026 3:30 PM
SAB Biotherapeutics (1833214) Filer
Form 424B3
08/14/2026 4:20 PM
PERCEPTIVE ADVISORS LLC (1224962) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G/A
08/14/2026 3:52 PM
Caligan Partners LP (1727492) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G/A
08/14/2026 10:04 AM
SAB Biotherapeutics (1833214) Subject
Woodline Partners LP (1784547) Filed by
Form SCHEDULE 13G/A
08/14/2026 5:08 AM
BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G/A
08/12/2026 11:08 AM
Adage Capital Management, L.P. (1535978) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
08/06/2026 6:56 AM
SAB Biotherapeutics (1833214) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/07/2026 7:15 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/26/2026 4:20 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 3:35 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2026 10:17 AM
Caligan Partners LP (1727492) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
05/15/2026 5:28 AM
BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
05/12/2026 6:35 AM
SAB Biotherapeutics (1833214) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/04/2026 3:35 PM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2026 3:57 PM
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
04/22/2026 7:13 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:35 PM
SAB Biotherapeutics (1833214) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/25/2026 3:35 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:25 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13D/A
03/10/2026 6:35 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2026 4:10 PM
SAB Biotherapeutics (1833214) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/17/2026 7:47 AM
RTW INVESTMENTS, LP (1493215) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G/A
02/05/2026 3:45 PM
Bausch Christoph Lawrence (1889981) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 3:50 PM
Reich Samuel J (1394645) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 3:55 PM
SAB Biotherapeutics (1833214) Issuer
Sullivan Eddie Joe (1889712) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 3:34 PM
PERCEPTIVE ADVISORS LLC (1224962) Filed by
SAB Biotherapeutics (1833214) Subject
Form SCHEDULE 13G
01/07/2026 11:15 PM
SAB Biotherapeutics (1833214) Filer
Form EFFECT
01/07/2026 3:40 PM
SAB Biotherapeutics (1833214) Issuer
ZACCARDELLI DAVID (1627642) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:41 PM
Jain Rita (1707797) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:35 PM
SAB Biotherapeutics (1833214) Issuer
ZACCARDELLI DAVID (1627642) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/07/2026 3:36 PM
Jain Rita (1707797) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/07/2026 7:30 AM
SAB Biotherapeutics (1833214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 9:08 AM
SAB Biotherapeutics (1833214) Filer
Form S-3
Registration statement under Securities Act of 1933  
12/18/2025 3:45 PM
Ellias Helen K. (2001600) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:50 PM
Lucera Erick (1697616) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:53 PM
Polvino William James (1889459) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:40 PM
Link David (2085171) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:43 PM
Giberson Scott (1937585) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:30 PM
SAB Biotherapeutics (1833214) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/12/2025 3:45 PM
Kropotova Alexandra (1825323) Reporting
SAB Biotherapeutics (1833214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
A new income category is drawing serious money - here's why (Ad)

Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.tc pixel

Watch the short briefing to see how this income approach works
11/12/2025 3:45 PM
SAB Biotherapeutics (1833214) Filer
Form 424B3
(Data available from 1/1/2016 forward)

SAB Biotherapeutics SEC Filings - Frequently Asked Questions

SAB Biotherapeutics (SABSW) has submitted 226+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 8-K submitted on October 13, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:SABSW are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/13/2026. New filings are added as they're published.
From Our Partners